HB 500
Alternative Names: HB-500Latest Information Update: 16 Aug 2024
At a glance
- Originator Hookipa Pharma
- Class AIDS vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I HIV infections
Most Recent Events
- 08 Aug 2024 Pharmacodynamics data from preclinical trial in HIV infections released by Hookipa Pharma
- 01 Jul 2024 Phase-I clinical trials in HIV infections (In adults, In the elderly, Treatment-experienced) in USA (IM) (NCT06430905)
- 21 Dec 2023 Hookipa Pharma plans a phase I trial for HIV infections in Q2 of 2024